A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial

G M Mead, M H Cullen, R Huddart, P Harper, G J S Rustin, P A Cook, S P Stenning, M Mason, MRC Testicular Tumour Working Party, G M Mead, M H Cullen, R Huddart, P Harper, G J S Rustin, P A Cook, S P Stenning, M Mason, MRC Testicular Tumour Working Party

Abstract

This phase II trial describes the use of TIP chemotherapy (paclitaxel, ifosfamide and cisplatin) as salvage for patients with metastatic germ cell cancer (GCC) who have failed initial BEP (bleomycin, etoposide and cisplatin) chemotherapy. Patients with first relapse following BEP for metastatic GCC, confirmed by biopsy or sequentially rising markers, received four courses of TIP (paclitaxel 175 mg m(-2) day 1, followed on days 1-5 by ifosfamide 1 g m(-2) intravenously (i.v.) and cisplatin 20 mg2 i.v.) at 3-weekly intervals. The primary outcome measure was response to TIP. In all, 51 patients were registered, of whom 43 were eligible for response assessment. Eight achieved complete remission (CR) and 18 a partial remission with negative markers (PR(-ve)); favourable response rate (FRR = CR + PR(-ve)) 60%, 95% CI (44-75%); survival at 1 year was 70% (56-84%) and failure-free survival 36% (22-50%). In the group of 26 patients meeting the 'good-risk' criteria described by the Memorial Hospital, the FRR was 73% (52-88%) compared with 41% (18-67%) for the 17 'poor-risk' patients. These results are inferior to those previously reported for TIP in a single-centre study when it was given more intensively, at higher dose and with growth factor support. Nonetheless, TIP as described here can cure a substantial proportion of patients.

Figures

Figure 1
Figure 1
Failure-free survival, all eligible patients.
Figure 2
Figure 2
Failure-free survival by risk group.
Figure 3
Figure 3
Survival, all eligible patients.
Figure 4
Figure 4
Survival by risk group.

References

    1. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of testicular cancer. J Clin Oncol 13: 1170–1176
    1. Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, Huhn D, Siegert W (1997) Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 79: 161–168
    1. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W (2002) High dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 13: 599–605
    1. Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols CR, Cornetta K, Einhorn LH (2000) High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18: 3346–3351
    1. Bokemeyer C, Bayer J, Metzner B, Ruther U, Harstrick A, Weissbach L, Kohrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31–34
    1. Bokemeyer C, Gerl A, Schoffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17: 12–516
    1. de Wit R, Roberts T, Wilkinson PM, De Mulder P, Mead GM, Fossa SD, Cook P, de Prijk L, Stenning S, Collette L (2001) Equivalence of three or four cycles of bleomycin, etoposide and cisplatin chemotherapy and of a 3- or 5-day schedule in good prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Co-operative Group and the Medical Research Council. J Clin Oncol 19: 1629–1640
    1. Donadio AC, Sheinfeld J, Bacik J, Mazumdar M, Marion S, Bajorin DF, Bosl GJ, Motzer RJ (2003) Paclitaxel, ifosfamide and cisplatin (TIP): an effective second-line therapy for patients with relapsed testicular germ cell tumours. Proc ASCO (Abstr) 22: 1537
    1. Einhorn LH, Stender MJ, Williams D (1999) Phase II trial of gemcitabine in refractory germ cell tumours. J Clin Oncol 17: 509–511
    1. Farhat F, Culine S, Theodore C, Bekradda M, TerrierLacombe MJ, Droz JP (1996) Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. Cancer 77: 1193–1197
    1. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark P, Wilkinson P, Jones W (1999) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80: 1392–1399
    1. Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W (1995) Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 72: 1026–1032
    1. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W (1997) Late relapse of germ cell tumours after cisplatin-based chemotherapy. Ann Oncol 8: 41–47
    1. Hinton S, Catalano PJ, Einhorn LH, Nichols CR, Crawford ED, Vogelzang N, Trump D, Loehrer PJ (2002) Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Co-operative Oncology Group. J Clin Oncol 20: 1859–1863
    1. Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Rick O, Hartmann JT, Stengele K, Hohloch K, Spott C, Kanz L, Bokemeyer C (2004) Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 22: 108–114
    1. Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C (2002a) Activity of oxaliplatin in patients with relapsed or cisplatin refractory germ cell cancer: A study of the German Testicular cancer Study Group. J Clin Oncol 20: 2031–2037
    1. Kollmannsberger C, Rick O, Klaproth H, Kubin T, Sayer HG, Hentrich M, Welslau M, Mayer F, Kuczyk M, Spott C, Kanz L, Bokemeyer C (2002b) Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German testicular Cancer Study Group. Br J Cancer 87: 729–732
    1. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumour. J Clin Oncol 16: 2500–2504
    1. Madani AA, George DW, Brames JM, Einhorn L (2003) Phase II study of epirubicin plus cisplatin in refractory germ cell tumors. Proc ASCO (Abstr) 22: 388
    1. McCaffrey JA, Mazumdar M, Bajorin D, Bosl GJ, Vlamis V, Motzer RJ (1997) Ifosfamide and cisplatin chemotherapy as first line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559–2563
    1. Miki T, Mizutani Y, Nonomura N, Nomoto T, Nakao M, Saiki S, Kotake T, Okuyama A (2002) Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 95: 1879–1885
    1. Miller KD, Loehrer PJ, Gonin R, Einhorn LH (1997) Salvage chemotherapy with vinblastine, ifosfamide and cisplatin in recurrent seminoma. J Clin Oncol 15: 1427–1431
    1. Motzer R, Bajorin D, Schwartz L, Hutter H, Bosl G, Scher H, Lyn P, Fischer P, Motzer RJ, Bajorin DF, Schwartz LH (1994) Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12: 2277–2283
    1. Motzer R, Gulati S, Crown J, Weisen S, Doherty M, Herr H, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl G (1992) High dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69: 550–556
    1. Motzer RJ, Geller NL, Tan CC-Y, Herr H, Morse M, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl G (1991) Salvage chemotherapy for patients with germ cell tumours. The Memorial Sloan-Kettering Cancer center experience (1979–1989). Cancer 67: 1305–1310
    1. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ (2000a) Sequential dose intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18: 1173–1180
    1. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D, Bosl GJ (2000b) Paclitaxel, ifosfamide and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18: 2413–2418
    1. Pizzocaro G, Salvioni R, Piva L, Faustini M, Nicolai N, Gianni L (1992) Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long term results. Ann Oncol 3: 211–216
    1. Pont J, Bokemeyer C, Harstrick A, Sellner F, Greinix H, Stoiber F (1997) Chemotherapy for germ cell tumors relapsing after high-dose chemotherapy and stem cell support: A retrospective multicenter study of the Austrian Study Group on Urologic Oncology. Ann Oncol 8: 1229–1234
    1. Porcu P, Bhatia S, Sharma M, Einhorn LH (2000) Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 18: 1181–1186
    1. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel WE, Kanz L, Siegert W (2001) Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19: 81–88
    1. Rosti G, Pico J, Wandt H, Koza V, Salvioni R, Theodore C, Lelli G (2002) High dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy in advanced germ cell tumours (GCT); first results of a prospective randomised trial of the European group for blood and marrow transplantation (EBMT): IT-94 study. Proc ASCO (Abstr) 21: 716
    1. Sandler AB, Cristou A, Fox S, Williams SD, Nichols CR, Turns M, Roth BJ (1998) A phase II trial of paclitaxel in refractory germ cell tumors. Cancer 82: 1381–1386

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir